skip to Main Content

Medicare (CMS) May 28th 2018 Local Coverage Determination (LCD) Updates

Medicare (CMS) May 28th 2018 Local Coverage Determination (LCD) Updates
Centers for Medicare & Medicaid Services (CMS) Local Coverage Determination (LCD) Updates

Centers for Medicare & Medicaid Services (CMS) Local Coverage Determination (LCD) Updates »

May 28th 2018 LCD Updates:

  • L34549              Ambulance Services
  • L34411              Blepharoplasty, Eyelid Surgery, and Brow Lift
  • L35490              Category III Codes
  • L33279 (retired)  Circulating Tumor Cell Testing
  • A55993              Circulating tumor cell testing retired Part A and Part B LCD
  • L35121              Coronary Computed Tomography Angiography (CCTA)
  • L34741              Drugs and Biologics (Non-chemotherapy)
  • A55951              Endometrial Hyperplasia Treatment with Intrauterine Device (Hormone-Eluting)
  • L34074              Immune Globulin Intravenous (IVIg)
  • L34314              Immune Globulin Intravenous (IVIg)
  • L34580              Intravenous Immunoglobulin (IVIG)
  • L36521              Lumbar Epidural Injections
  • A55137              MolDX 4q25-AF Risk Genotype Testing Coding and Billing Guidelines
  • L35443              MolDX: GeneSight ® Assay for Refractory Depression
  • L37013              MolDX: 4Kscore Assay
  • A55138              MolDX: 9p21 Genotype Test Coding and Billing Guideline
  • A55139              MolDX: Afirma™ Assay by Veracyte Update
  • A55140              MolDX: AlloMap Billing and Coding Guidelines Update
  • L36882              MolDX: APC and MUTYH Gene Testing
  • L36884              MolDX: APC and MUTYH Gene Testing
  • A55141              MolDX: ApoE Genotype Coding and Billing Guidelines
  • A55142              MolDX: Aspartoacyclase 2 Deficiency (ASPA) Testing Coding and Billing Guidelines
  • A55143              MolDX: ATP7B Gene Tests Coding and Billing Guidelines
  • A55144              MolDX: Avise PG Assay Billing/Coding Update
  • A54188              MolDX: bioTheranostics Cancer TYPE ID® Update
  • A55147              MolDX: bioTheranostics Cancer TYPE ID® Update
  • A55970              MolDX: CDH1 Genetic Testing Billing and Coding Guidelines
  • A55971              MolDX: CDH1 Genetic Testing Billing and Coding Guidelines
  • A54878              MolDX: CDH1 Genetic Testing Coding and Billing Guidelines
  • A55622              MolDX: CDH1 Genetic Testing Coding and Billing Guidelines
  • L36327              MolDX: ConfirmMDx Epigenetic Molecular Assay
  • L36329              MolDX: ConfirmMDx Epigenetic Molecular Assay
  • A55234              MolDX: CYP2B6 Test Coding and Billing Guidelines
  • A54687              MolDX: CYP2C9 and/or VKORC1 Gene Testing for Warfarin Response Coding and Billing Guidelines
  • L36656              MolDX: Decipher® Prostate Cancer Classifier Assay
  • A54262              MolDX: ENG and ACVRL1 Gene Tests Coding and Billing Guidelines
  • A54265              MolDX: GBA Genetic Testing Coding and Billing Guidelines
  • L36799              MolDX: GeneSight® Assay for Refractory Depression
  • A55166              MolDX: HBB Gene Tests Coding and Billing Guidelines
  • A55168              MolDX: HEXA Gene Analysis Coding and Billing Guidelines
  • A55169              MolDX: HTTLPR Gene Testing Coding and Billing Guidelines
  • A55170              MolDX: IKBKAP Genetic Testing Coding and Billing Guidelines
  • A55171              MolDX: KIF6 Genotype Billing and Coding Guidelines
  • A55172              MolDX: know error® Billing and Coding Guidelines Update
  • A55192              MolDX: L1CAM Gene Sequencing Coding and Billing Guidelines
  • A55173              MolDX: LPA-Aspirin Genotype Coding and Billing Guidelines
  • A55174              MolDX: LPA-Intron 25 Genotype Coding and Billing Guidelines
  • A55189              MolDX: MECP2 Genetic Testing Coding and Billing Guidelines
  • A54338              MolDX: Myriad’s BRACAnalysis CDx™ Coding and Billing Guidelines
  • L36803              MolDX: NSCLC, Comprehensive Genomic Profile Testing
  • A54223 (retired) MolDX: Response to Comments for Molecular RBC Phenotyping
  • A55205              MolDX: RPS19 Gene Tests Coding and Billing Guidelines
  • A55621              MolDX: Short Tandem Repeat (STR) Markers and Chimerism (codes 81265-81268) Coding and Billing Guidelines
  • A54283              MolDX: SULT4A1 Genetic Testing Coding and Billing Guidelines
  • L34518              Molecular Pathology Procedures for Human Leukocyte Antigen (HLA) Typing
  • L35755              Non-Invasive Abdominal / Visceral Vascular Studies
  • L35753              Non-Invasive Cerebrovascular Studies
  • L35761              Non-Invasive Peripheral Arterial Vascular Studies
  • L35751              Non-Invasive Peripheral Venous Vascular and Hemodialysis Access Studies
  • A55640              Not Otherwise Classified Chemotherapy Agents (NOC)
  • L36775              Prostatic Urethral Lift (PUL)
  • A55990              Prostatic urethral lift (PUL) revision to the Part A and Part B LCD
  • A54567 (retired) Response to Comments for MolDX: BRCA1 and BRCA2 Genetic Testing
  • A54565 (retired) Response to Comments for MolDX: Breast Cancer Assay: Prosigna
  • A55537 (retired) Response to Comments: Coenzyme Q10 (CoQ10)
  • A54755 (retired) Response to Comments: MolDX: Breast Cancer Assay: Prosigna LCD L36125
  • A52452              Rituximab (Rituxan®) – Related to LCD L33394
  • A52800              Self-Administered Drug Exclusion List (SAD List)
  • L33447              Special Electroencephalography
  • L33762              Treatment of varicose veins of the lower extremity
  • L37015              Visual Electrophysiology Testing
  • L33771              Vitamin D; 25 hydroxy, includes fraction(s), if performed
  • A55991              Vitamin D; 25 hydroxy, includes fraction(s), if performed revision to the Part A and Part B LCD
  • L36690              Wound Application of Cellular and/or Tissue Based Products (CTPs), Lower Extremities

 

Centers for Medicare & Medicaid Services (CMS) Local Coverage Determination (LCD) Updates »

 

Policy Alerts monitors Commercial and Medicare medical policies for changes. While medical Insurance carriers typically update medical policies annually, there are many reasons why they might review or update a policy. When reviews occur out of cycle they often go unnoticed. Policy Alerts keeps you updated when Payers make coverage changes to medical policies affecting your business.

Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on medical Insurance decisions in real-time. When changes occur, instant email alerts are delivered to your inbox. Clients have access to detailed coverage reports and medical policies through the interactive Policy Alerts Dashboard portal. Save time each month and keep focused on important Payer medical policy reviews and coverage decisions affecting your business!

Policy Alerts takes a client-focused hands-on approach and is constantly working to provide our customers with helpful insights and actionable analytics. We understand what our clients need and are dedicated to providing timely, accurate, and always up-to-date reports.

Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.

Back To Top